Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
Browsing: Basic > Pre-clinical Trials
Researchers at Scripps Research Institute have used the blood of recovered COVID-19 patients to identify potent antibodies that protect against SARS-CoV-2. The study, published in Science, has shown the antibodies’ successful use in animal models and human cell cultures.
Researchers have demonstrated that two COVID-19 vaccine candidates can protect against COVID-19 in primates, with re-exposure triggering an immune response in rhesus macaques.
Researchers at the Korea Institute of Science and Technology (KIST) and Catholic University of Korea (CUK) have developed a vaccine platform against MERS coronavirus (MERS-CoV) that could be used to develop a vaccine for COVID-19.
Building on their previous research into SARS-CoV, researchers have identified a human monoclonal antibody capable of preventing both SARS-CoV and SARS-CoV-2 from infecting cultured cells. This cross-neutralizing feature could potentially mitigate future related coronaviruses.
Researchers and pharmacists have cautioned against the use of malaria drugs hydroxychloroquine and chloroquine for the treatment of COVID-19, warning against premature optimism that these drugs are effective and safe for use in COVID-19 patients.
A new study suggests that a human recombinant soluble enzyme blocker, hrsACE2, significantly reduces SARS-CoV-2 viral load in human tissue, suggesting it could have the potential to prevent COVID-19.
Researchers from the University of Pittsburgh (PA, USA) have revealed the results from preclinical research testing their COVID-19 vaccine candidate in mice.